Severe Atopic Dermatitis

A 4 mg dose of baricitinib plus topical corticosteroids was associated with significant improvement over placebo in a phase 3 study of patients with moderate to severe atopic dermatitis, according to a study.

Cibinqo safely and effectively treated moderate to severe atopic dermatitis among patients regardless of any previous treatment with Dupixent, according to data published in the Journal of the American Academy of Dermatology.

Treatment with tralokinumab significantly improved symptoms among adolescents with moderate to severe atopic dermatitis, according to a study presented at the Western Society of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has accepted for priority review a supplemental biologics application for Dupixent that could allow treatment of moderate to severe atopic dermatitis in patients aged 6 months to 5 years, Regeneron announced in a press release.

The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.

Severe atopic dermatitis is associated with depression and internalizing behaviors in childhood and adolescence, according to a study.

Methotrexate and azathioprine yielded similar risk-benefit ratios as first-line therapy for children with severe atopic dermatitis, according to a study.

Induction therapy with abrocitinib was associated with low flare rates in patients with moderate to severe atopic dermatitis, according to a study.

The phase 3 JADE COMPARE trial met its co-primary efficacy endpoints in adults with moderate to severe atopic dermatitis. Results from the trial, which compared the use of the JAK1 inhibitor abrocitinib with placebo, will be submitted for presentation at a future conference, according to a press release from Pfizer.

Eli Lilly and Company and Incyte announced that baricitinib met its primary endpoint in the BREEZE-AD4 and BREEZE-AD5 studies in patients with moderate to severe atopic dermatitis, according to two press releases.